Diabetes drug trial offers new hope for stubborn asthma
NCT ID NCT05254314
Summary
This study is testing if semaglutide, a medication already approved for diabetes and weight loss, can help control asthma in adults who are overweight and still have symptoms despite using standard inhalers. One hundred participants will be randomly assigned to receive either the drug or a placebo for 24 weeks to see if it improves their asthma symptoms and reduces airway inflammation. The goal is to see if this drug offers a new way to manage difficult-to-control asthma linked to obesity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.